Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells

Vi Lam, Tingting Liu, Haifeng Shen, Olga Danilova, Katarzyna Dabrowska, Sonia Rodriguez-Rodriguez, Courtney Jones, Martina Cusan, Angelo D'Alessandro, Lapo Alinari, Lili Wang, Tycel Phillips, Patrick Pirrotte, Zheng Xia, Alexey Danilov

Blood (2025) 146 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2025-5087

Published: 2025

Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2025-5513

Published: 2025

Journal Articles

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Chan Cheah, Tycel Phillips, Wojciech Jurczak, Tae Min Kim, Kim Linton, Julie Vose, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Charles Kearns, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5511.

https://doi.org/10.1182/blood-2025-5511

Published: 2025

Journal Articles

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Blood (2025) 146 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2025-5373

Published: 2025

Journal Articles

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

Preetesh Jain, Anna Teschemaker, Essam Ibrahim, Taavy Miller, Danni Zhao, Ayush Kris, Ahmed Sawas, Debbie Adkins, Anouchka Chelles, Victoria Otero, Tycel Phillips

Blood (2025) 146 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2025-4482

Published: 2025

Journal Articles

Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up

Catherine Thieblemont, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Cheah, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Derek Woods, Tycel Phillips

Blood (2025) 146 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2025-1960

Published: 2025

Journal Articles

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Krish Patel, Jennifer Crombie, Tycel Phillips, Michael Dickinson, Toby Eyre, Chan Cheah, Stephen Schuster, Nirav Shah, Georg Lenz, Laurie Sehn, Donald Tsai, Erica Johnston, Sonya Chapman, Hongmei Han, Minna Balbas, Ching Ching Leow, Gilles Salles

Blood (2025) 146 (Supplement 1): 5524.

https://doi.org/10.1182/blood-2025-5524

Published: 2025

Journal Articles

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

Amber Williams, Kristen Rosenthal, Stephen Ansell, Ian Flinn, Brad Kahl, Tycel Phillips, Julie Vose, Timothy Quill

Blood (2025) 146 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2025-4650

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Tycel Phillips, Mengyang Di, Taavy Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene Kuizon Seymour, Yucai Wang

Blood (2024) 144 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2024-208063

Published: 2024

Journal Articles

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Henry Dumke, Kellen Fitzpatrick, Tycel Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox, Dahlia Sano, Malathi Kandarpa, Avery Polk, Benjamin L Viglianti, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2024-203822

Published: 2024

Journal Articles

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

John M. Burke, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, Tycel Phillips

Blood (2024) 144 (Supplement 1): 7810.

https://doi.org/10.1182/blood-2024-203554

Published: 2024

Journal Articles

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Tycel Phillips, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, John M. Burke

Blood (2024) 144 (Supplement 1): 7809.

https://doi.org/10.1182/blood-2024-203380

Published: 2024

Journal Articles

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Anne W Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J Alencar, Shira N. Dinner, Eric D. Hsi, Meng Welliver, Daniel Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 1661.3.

https://doi.org/10.1182/blood-2024-207372

Published: 2024

Journal Articles

Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)

Paolo Lopedote, Geoffrey Shouse, Alexandra Muir, Carly Rolender, Peter Sportelli, Hari Miskin, Lu Chen, Tycel Phillips, Alexey Danilov

Blood (2024) 144 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2024-200963

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2022) 140 (Supplement 1): 6477–6479.

https://doi.org/10.1182/blood-2022-157595

Published: 2022

Journal Articles

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Tycel Phillips, Junhua Yu, Rajesh Kamalakar, Kalatu R. Davies, Alex Mutebi, Savreet Bains Chawla, Donald Arnette, Syed Quadri, Anthony Wang

Blood (2022) 140 (Supplement 1): 5241–5243.

https://doi.org/10.1182/blood-2022-157773

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only